Business Wire

CA-REGOLOGY

Share
Regology Raises $8M Series A to Scale AI-based Regulatory Compliance Platform

Regology , a company automating enterprise compliance with AI, today announced an $8 million Series A round led by ACME Capital .

Regology offers an AI-enabled platform that actively tracks regulatory updates, allowing companies to dynamically monitor changes to business-relevant laws, identify emerging risks and fines, and set up controls to ensure legal requirements are being met. By automating tasks that typically take companies months to complete manually, Regology empowers enterprises to streamline resources spent on regulatory compliance efforts with improved results.

“With regulations constantly changing at local, federal and global levels, it’s impossible for companies to stay current with human intelligence alone,” said Mukund Goenka, co-founder and CEO, Regology. “Whether it is allowing banks to share financial transaction data or ensuring COVID requirements are met, Regology is helping companies deliver on the promise to be up to date and legal, without headache and human error.”

Based on Regology’s market analysis, in 2020 Global 500 companies spent more than $400 billion on regulatory compliance, yet were fined over $20 billion. The Regology platform aims to solve this gap by providing companies instant access to law progressions, from initial bill to law passage, to subsequent publication coverage and updates across jurisdictions. Its proprietary AI algorithm allows companies to track regulatory updates in real time at the industry, product and functional level, ensuring their business keeps pace with the dynamics of regulations. By automating processes, companies are prepared to enter new markets faster while reducing their risk profile and operational costs.

“Legal and compliance has traditionally been hyper localized, making disparate information and fragmented systems inevitable, even for the most sophisticated companies,” said Hany Nada, co-founder and partner at ACME Capital. “The past year called to light how quickly regulation changes. Regology helps global enterprises keep pace with that change, providing peace of mind to business leaders and operators.”

Regology has built the largest unified database of more than 94 million requirements across millions of sections of law for the Technology and Banking industries, covering 25 countries, more than 1,000 agencies and eight languages. The new capital will be used to further develop its AI platform and expand its team with new hires in engineering and sales.

About Regology

Regology is an AI-based regulatory compliance solution that standardizes the regulatory change and compliance process. Regology serves multiple industries, including energy, financial services, healthcare, infrastructure, manufacturing, real estate, technology, telecommunications, transportation, and utilities; and functional areas, including anti-corruption, consumer protection, data privacy, environmental safety, food safety, health and human safety, labor and employment, physical security, product safety, responsible sourcing, trade control, and supply chain. For more information, visit https://regology.com .

About ACME

ACME is a San Francisco-based early-stage venture capital firm investing in breakthrough enabling technologies and business model innovations disrupting massive sectors. We partner with entrepreneurs around the world who work with significant technologies making a positive impact for the consumers of the future. For more information, go to: https://www.acme.vc

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ant Group Unveils China’s First Multimodal AI Assistant with Code-Driven Outputs18.11.2025 09:05:00 CET | Press release

Ant Group today launched LingGuang, a next-generation multimodal AI assistant and the first of its kind in China that interacts with users through code-driven outputs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117438567/en/ Equipped with the capability to understand and produce language, image, voice and data, LingGuang delivers precise, structured responses to complex queries through 3D models, audio clips, charts, animations, interactive maps, and even immediately generated applications, in addition to traditional text-based conversation. Designed around three key features, LingGuang aims to make complex knowledge simpler and more intuitive, transforming how users access information and interact with AI tools. Fast Research: LingGuang responds to user questions or keywords with dynamic, multimodal content, making research on any topic clearer and more engaging. Its 3D digital modeling capability transcends traditio

SkySparc Appoints Oliver Bussmann as Chairman of the Board18.11.2025 09:00:00 CET | Press release

Appointment of industry veteran follows majority growth investment from Bregal Milestone SkySparc, a trusted global provider of digital transformation solutions for treasury and finance organizations, today announced the appointment of Oliver Bussmann as Chairman of the Board, following the closing of a majority growth investment from Bregal Milestone, a leading European software private equity firm. As former Global CIO at UBS and SAP, Bussmann has a proven track record of scaling B2B software and services across the Office of the CFO, Financial Services, RegTech, and WealthTech. Throughout his career, he has guided organizations through complex SaaS transitions, strategic M&A, and go-to-market acceleration – delivering multiple successful exits and sustained enterprise growth. Bussmann will help steer SkySparc’s technology and value-creation agenda, as Chairman, leveraging his network across financial services and technology to accelerate innovation, expand AI adoption, and drive lon

European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 08:23:00 CET | Press release

Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for Remsima™ IV powder formulation1The approval is based on the comparability data between infliximab powder formulation and the liquid formulation2The new liquid formulation of infliximab, available in 100 mg and a newly introduced 350 mg presentation, eliminates the need for reconstitution and cuts drug preparation time by 51%, lowering preparation costs by 20%1,3Projected annual cost savings across seven European countries could reach up to €2.6 million, alongside significant improvements to workflow efficiency3 Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline inf

Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release

After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa

Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release

MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye